Gene therapy for therapeutic angiogenesis in peripheral arterial disease- A systematic review and meta-Analysis of randomized, controlled trials;Gentherapie zur therapeutischen Angiogenese bei peripherer arterieller Verschlusskrankheit-Ein systematischer review und Metaanalyse von randomisierten, kontrollierten Studien

Vasa - Journal of Vascular Diseases

Volumn 42, Issue 5, 2013, Pages 331-339

  Hammer, Alexandra ^a   Steiner, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Gene therapy; Peripheral arterial disease; Systematic review

Indexed keywords

ANGIOGENIC PROTEIN; DEVELOPMENTAL ENDOTHELIAL LOCUS 1; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMPUTATION; ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; FOLLOW UP; GENE THERAPY; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; META ANALYSIS; MORTALITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; ULCER HEALING; VISUAL ANALOG SCALE; WALKING;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CRITICAL ILLNESS; FEMALE; GENETIC THERAPY; HUMANS; ISCHEMIA; LIMB SALVAGE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84883319296     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000298     Document Type: Review

References (23)

1. Steg P G, Bhatt D L, Wilson P W, D'Agostino R, Sr., Ohman E M, Rother J, Liau C S, Hirsch A T, Mas J L, Ikeda Y, Pencina M J, and Goto S, One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007. 297 (11): 1197-206.
2. Tendera M, Aboyans V, Bartelink M L, Baumgartner I, Clement D, Collet J P, Cremonesi A, De Carlo M, Erbel R, Fowkes F G, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Rother J, Sievert H, van Sambeek M, and Zeller T, ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011. 32 (22): 2851-906.
3. Mughal N A, Russell D A, Ponnambalam S, and Homer-Vanniasinkam S, Gene therapy in the treatment of peripheral arterial disease. Br J Surg 2012. 99 (1): 6-15.
4. Attanasio S and Snell J, Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev 2009. 17 (3): 115-20.
5. Higgins J and Green S, Assessing risk of bias in included studies, in Cochrane Handbook for Systematic Reviews of Interventions. 2008, John Wiley & Sons. p. 187-241.
6. Higgins J P and Thompson S G, Quantifying heterogeneity in a meta-analysis. Stat Med 2002. 21 (11): 1539-58.
7. DerSimonian R and Laird N, Metaanalysis in clinical trials. Control Clin Trials 1986. 7 (3): 177-88.
8. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, and Yla-Herttuala S, Increased vascularity detected by digital subtraction angiography aft er VEGF gene transfer to human lower limb artery: a randomized, placebocontrolled, double-blinded phase II study. Molecular Therapy: the Journal of the American Society of Gene Therapy 2002. 6 (1): 127-33.
9. Rajagopalan S, Mohler E R r, Lederman R J, Mendelsohn F O, Saucedo J F, Goldman C K, Blebea J, Macko J, Kessler P D, Rasmussen H S, and Annex B H, Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, doubleblind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003. 108 (16): 1933-8.
10. Kusumanto Y H, van Weel V, Mulder N H, Smit A J, van den Dungen J J, Hooymans J M, Sluiter W J, Tio R A, Quax P H, Gans R O, Dullaart R P, and Hospers G A, Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Human Gene Therapy 2006. 17 (6): 683-91.
11. Grossman P M, Mendelsohn F, Henry T D, Hermiller J B, Litt M, Saucedo J F, Weiss R J, Kandzari D E, Kleiman N, Anderson R D, Gottlieb D, Karlsberg R, Snell J, and Rocha-Singh K, Results from a phase II multicenter, double-blind placebocontrolled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. American Heart Journal 2007. 153 (5): 874-80.
12. Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman P M, Goldman C K, McEllin K, Kelly R, and Chronos N, Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007. 115 (10): 1234-43.
13. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi M C, Ferreira-Maldent N, Gallino A, Wyatt M G, Wijesinghe L D, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, and Meyer F, Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008. 16 (5): 972-8.
14. Powell R J, Simons M, Mendelsohn F O, Daniel G, Henry T D, Koga M, Morishita R, and Annex B H, Results of a double-blind, placebocontrolled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008. 118 (1): 58-65.
15. Powell R J, Goodney P, Mendelsohn F O, Moen E K, and Annex B H, Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010. 52 (6): 1525-30.
16. Shigematsu H, Yasuda K, Iwai T, Sasajima T, Ishimaru S, Ohashi Y, Yamaguchi T, Ogihara T, and Morishita R, Randomized, doubleblind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010. 17 (9): 1152-61.
17. Anghel A, Taranu G, Seclaman E, Rata A, Tamas L, Moldovan H, Ursoniu S, Samoila C, Ionac M, and Popa-Wagner A, Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia. Current Neurovascular Research 2011. 8 (3): 183-9.
18. Belch J, Hiatt W R, Baumgartner I, Driver I V, Nikol S, Norgren L, and Van Belle E, Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011. 377 (9781): 1929-37.
19. Creager M A, Olin J W, Belch J J, Moneta G L, Henry T D, Rajagopalan S, Annex B H, and Hiatt W R, Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011. 124 (16): 1765-73.
20. Moher D, Liberati A, Tetzlaff J, Altman D G, and Group P, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009. 6(7): e1000097.
21. Gupta R, Tongers J, and Losordo D W, Human studies of angiogenic gene therapy. Circulation Research 2009. 105 (8): 724-36.
22. Niebuhr A, Henry T, Goldman J, Baumgartner I, Van Belle E, Gerss J, Hirsch A T, and Nikol S, Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease. Gene Therapy 2012. 19 (3): 264-270.
23. Pacilli A, Faggioli G, Stella A, and Pasquinelli G, An update on therapeutic angiogenesis for peripheral vascular disease. Annals of Vascular Surgery 2010. 24 (2): 258-68.